Literature DB >> 25372804

Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis.

Navjyot Hansi1, Nora Thoua, Maresa Carulli, Kuntal Chakravarty, Simon Lal, Anita Smyth, Ariane Herrick, Olagunju Ogunbiyi, Jon Shaffer, John Mclaughlin, Christopher Denton, Voon Ong, Anton V Emmanuel, Charles D Murray.   

Abstract

Systemic sclerosis is an autoimmune connective tissue disorder, which can be progressive with multisystem involvement. Guidance on the management of complications is based on a limited data set and practice amongst clinicians can vary. The UK Scleroderma study group set up several working groups to agree some consensus pathways for the management of specific complications. Approximately nine out of ten patients with systemic sclerosis will have involvement of the gastrointestinal system and in this review article we explore the management of these complications in a symptom-based approach. The algorithms are a useful tool for clinicians, which we hope, will be a point of reference and highlight the need for further research in these areas.

Entities:  

Mesh:

Year:  2014        PMID: 25372804

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  18 in total

Review 1.  Update on systemic sclerosis.

Authors:  Courtney J McCray; Maureen D Mayes
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

Review 2.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

Review 3.  Intestinal Involvement in Systemic Sclerosis: A Clinical Review.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Dimitrios Daoussis; Stamatis-Nick Liossis; Spyros Potamianos
Journal:  Dig Dis Sci       Date:  2018-02-21       Impact factor: 3.199

4.  Prevalence of malnutrition in systemic sclerosis patients assessed by different diagnostic tools.

Authors:  Anna Wojteczek; Jolanta A Dardzińska; Sylwia Małgorzewicz; Agnieszka Gruszecka; Zbigniew Zdrojewski
Journal:  Clin Rheumatol       Date:  2019-11-16       Impact factor: 2.980

5.  Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.

Authors:  Anna-Maria Hoffmann-Vold; Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-20

Review 6.  Radiological findings in gastrointestinal scleroderma.

Authors:  Stamatia-Lydia Chatzinikolaou; Bernadine Quirk; Charles Murray; Katie Planche
Journal:  J Scleroderma Relat Disord       Date:  2019-05-20

Review 7.  [Current treatment of systemic scleroderma].

Authors:  Nicolas Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

8.  Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Authors:  E K Stern; D A Carlson; S Falmagne; A D Hoffmann; M Carns; J E Pandolfino; M Hinchcliff; D M Brenner
Journal:  Neurogastroenterol Motil       Date:  2017-11-06       Impact factor: 3.598

9.  Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial.

Authors:  Anna-Maria Hoffmann-Vold; Håvard H Fretheim; Vikas K Sarna; Imon Barua; Maylen N Carstens; Oliver Distler; Dinesh Khanna; Elizabeth R Volkmann; Øyvind Midtvedt; Henriette Didriksen; Alvilde Dhainaut; Anne-Kristine Halse; Gunnstein Bakland; Maiju Pesonen; Inge Olsen; Øyvind Molberg
Journal:  BMJ Open       Date:  2021-06-24       Impact factor: 2.692

Review 10.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.